Jefferies Financial Group Inc. reduced its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 89.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,781 shares of the medical research company’s stock after selling 15,594 shares during the period. Jefferies Financial Group Inc.’s holdings in Quest Diagnostics were worth $415,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Quest Diagnostics in the second quarter worth $1,965,923,000. EdgePoint Investment Group Inc. boosted its stake in shares of Quest Diagnostics by 35.1% during the first quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock valued at $439,753,000 after purchasing an additional 582,797 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Quest Diagnostics by 0.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,949,535 shares of the medical research company’s stock valued at $382,085,000 after purchasing an additional 17,987 shares during the period. Bank of America Corp DE purchased a new stake in shares of Quest Diagnostics during the second quarter valued at $410,151,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Quest Diagnostics by 11.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 942,407 shares of the medical research company’s stock worth $199,743,000 after purchasing an additional 95,804 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.
Key Stories Impacting Quest Diagnostics
Here are a few of the latest stories about DGX:
- Positive Sentiment: Zacks Research raised several earnings forecasts, including its FY2026 EPS estimate to $11.28 from $11.15 and its Q2 2027 estimate to $3.09 from $2.99. The improved forecasts may support investor confidence, though the FY2026 estimate remains close to the $11.29 consensus.
- Positive Sentiment: Quest announced a quarterly dividend of $0.86 per share, equivalent to $3.44 annually and a stated yield of about 1.3%. The announcement coincided with DGX reaching a new one-year high. Quest Diagnostics hits a one-year high following dividend announcement
- Neutral Sentiment: SVP Patrick Plewman sold 11,717 shares for about $3.02 million, reducing his holdings by 44.38%. The sale was made under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive signal about his view of the company. Quest Diagnostics insider share sale
Insider Transactions at Quest Diagnostics
In other Quest Diagnostics news, EVP Catherine T. Doherty sold 22,105 shares of the stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $248.02, for a total transaction of $5,482,482.10. Following the transaction, the executive vice president directly owned 71,949 shares in the company, valued at $17,844,790.98. This represents a 23.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Michael E. Prevoznik sold 22,677 shares of the firm’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $243.11, for a total transaction of $5,513,005.47. Following the transaction, the senior vice president directly owned 37,557 shares in the company, valued at $9,130,482.27. This trade represents a 37.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 67,702 shares of company stock valued at $16,730,269 over the last three months. 0.88% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Several research analysts recently commented on DGX shares. Robert W. Baird set a $262.00 price target on shares of Quest Diagnostics in a research note on Friday, October 23rd. Mizuho lifted their price objective on shares of Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Argus set a $260.00 price objective on shares of Quest Diagnostics in a research report on Wednesday, July 29th. Truist Financial upped their target price on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock a “hold” rating in a research note on Monday, September 21st. Finally, Barclays upped their target price on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $248.70.
View Our Latest Report on Quest Diagnostics
Quest Diagnostics Trading Down 0.1%
Shares of NYSE DGX opened at $259.46 on Monday. The company has a quick ratio of 1.58, a current ratio of 1.70 and a debt-to-equity ratio of 0.70. The business has a fifty day simple moving average of $241.23 and a two-hundred day simple moving average of $215.58. The firm has a market cap of $28.55 billion, a PE ratio of 25.84, a price-to-earnings-growth ratio of 2.32 and a beta of 0.54. Quest Diagnostics Incorporated has a twelve month low of $171.18 and a twelve month high of $262.00.
Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its earnings results on Thursday, October 22nd. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.87 by $0.13. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. The business had revenue of $3.10 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same period in the prior year, the business earned $2.60 EPS. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. Analysts expect that Quest Diagnostics Incorporated will post 11.29 earnings per share for the current fiscal year.
Quest Diagnostics Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 27th. Investors of record on Tuesday, January 12th will be issued a $0.86 dividend. This represents a $3.44 annualized dividend and a dividend yield of 1.3%. The ex-dividend date is Tuesday, January 12th. Quest Diagnostics’s payout ratio is presently 34.26%.
Quest Diagnostics Company Profile
Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.
See Also
- Five stocks we like better than Quest Diagnostics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
